# 10x Genomics, Inc.  Share Price Target ‘$57.79’, now 61.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/10x-genomics-inc.share-price-target-57.79-now-61.7-upside-potential/4121150523
- Published: 2024-04-05T15:03:48+01:00
- Author: Charlotte Edwards

**10x Genomics, Inc.** which can be found using ticker (TXG) now have 14 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The target
price High/Low ranges between $70.00 and $30.00 and has a mean share price target
at $57.79. (at the time of writing). Given that the stocks previous close was at
$35.74 and the analysts are correct then we can expect a percentage increase in 
value of 61.7%. It’s also worth noting that there is a 50 day moving average of 
$42.27 and the 200 moving average now moves to $46.73. The company has a market 
cap of 4.29B. The stock price is currently at: $35.97 USD

 The potential market cap would be $6,930,979,328 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $5.28 and
a -12.22% return on assets.

10x Genomics, Inc. is a life science technology company. The Company’s integrated
platform solutions include instruments, consumables and software for analyzing biological
systems. Its Chromium platform includes its Chromium X Series, Chromium Connect 
and legacy Chromium Controller instruments, microfluidic chips and related consumables,
enables throughput analysis of individual biological components. Its Visium platform
enables researchers to understand the spatial positions of biological analytes within
tissues at high resolution. Its products include Chromium Single Cell Gene Expression,
Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling,
Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium
Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, Visium
Spatial Proteogenomics and Xenium In Situ Gene Expression. Its patent portfolio 
comprises over 1,750 issued patents and patent applications.

Share on: